Summary
A research-focused comparison of semaglutide, tirzepatide, and retatrutide — three incretin-based compounds across two generations of metabolic research, examining their mechanisms, clinical trial data, and key differences.
The Evolution of Incretin-Based Research
Three compounds. Three generations of mechanism. One converging research question: how far can targeted hormonal signalling take metabolic science?
Semaglutide, tirzepatide, and retatrutide represent consecutive steps in the development of incretin-based therapeutics — a field that has produced some of the most significant clinical trial data in the history of obesity and metabolic disease research.
Each compound adds a receptor to the previous one:
- Semaglutide — GLP-1 receptor agonist (single target)
- Tirzepatide — GLP-1 + GIP receptor agonist (dual target)
- Retatrutide — GLP-1 + GIP + Glucagon receptor agonist (triple target)
Understanding what each additional receptor contributes — and what the published data says about outcomes — is the core question this article addresses.
Background: The Incretin System
Before comparing the compounds, it helps to understand the hormonal system they operate within.
Incretins are gut-derived hormones released in response to food intake. Their primary role is to amplify insulin secretion from the pancreas in a glucose-dependent manner — meaning they stimulate insulin release only when blood glucose is elevated, which limits hypoglycaemia risk.
The two principal incretins studied in this context are:
GLP-1 (Glucagon-like Peptide-1) — secreted by L-cells in the small intestine and colon. Beyond insulin stimulation, GLP-1 also:
- Suppresses glucagon (which would otherwise raise blood glucose)
- Slows gastric emptying, reducing post-meal glucose spikes
- Acts on hypothalamic satiety centres to reduce appetite
- Has demonstrated cardiovascular protective effects in clinical trials
GIP (Glucose-dependent Insulinotropic Polypeptide) — secreted by K-cells in the duodenum. Its role was long considered limited to insulin augmentation, but research has revealed additional metabolic effects including direct adipocyte signalling and energy expenditure modulation.
Glucagon — not an incretin, but a pancreatic hormone that raises blood glucose by stimulating hepatic glucose production and promoting fat breakdown. In the context of triple agonism, low-level glucagon receptor activation is studied for its contribution to energy expenditure and lipolysis, partially offsetting the hyperglycaemic effect through the compound's GLP-1 activity.
Semaglutide
Mechanism
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is a modified analogue of human GLP-1, engineered for resistance to enzymatic degradation and albumin binding — extending its half-life to approximately one week, enabling once-weekly dosing.
Its mechanism is entirely GLP-1 mediated:
- Glucose-dependent insulin stimulation
- Glucagon suppression
- Delayed gastric emptying
- Central appetite suppression via hypothalamic receptors
Key Clinical Trial Data
STEP programme (obesity): In STEP 1, once-weekly semaglutide 2.4 mg produced a mean body weight reduction of 14.9% over 68 weeks versus 2.4% for placebo. Approximately 70% of participants achieved at least 5% weight loss; one-third achieved at least 15%.
SUSTAIN programme (type 2 diabetes): Demonstrated HbA1c reductions of 1.5-1.8% alongside weight loss of 3-6 kg over 30-40 weeks across multiple trials.
SELECT cardiovascular trial: In people with cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% versus placebo — a landmark finding that substantially broadened the clinical relevance of GLP-1 research.
Side Effect Profile in Research
- Nausea, vomiting, and diarrhoea — most common, typically dose-dependent and transient
- Constipation reported in a subset
- Rare: pancreatitis signals in some studies (relationship not established causally)
- Gastroparesis-adjacent slowing of gastric motility at higher doses
Tirzepatide
Mechanism
Tirzepatide, developed by Eli Lilly, adds GIP receptor agonism to GLP-1 activity. It is a single synthetic peptide designed as a "twincretin" — activating both receptors simultaneously with balanced potency.
The addition of GIP activity contributes several mechanisms that are distinct from or additive to GLP-1:
- Direct adipocyte signalling: GIP receptors are expressed on fat cells. GIP agonism has been shown to influence lipid storage and mobilisation directly at the tissue level — an effect absent from pure GLP-1 agonists.
- Enhanced insulin secretion: GIP and GLP-1 together produce greater insulin augmentation than either alone — their combination is synergistic rather than merely additive.
- Potential energy expenditure: Some research suggests GIP receptor activity may independently influence thermogenesis and metabolic rate, though the magnitude in humans remains under study.
- Improved tolerability: Paradoxically, the addition of GIP activity appears to reduce gastrointestinal side effects compared to equivalent doses of pure GLP-1 agonists — a finding that has been observed consistently across tirzepatide trials.
Key Clinical Trial Data
SURMOUNT programme (obesity): In SURMOUNT-1, tirzepatide at 15 mg produced a mean body weight reduction of 20.9% over 72 weeks versus 3.1% for placebo — surpassing the weight loss data for semaglutide from STEP trials. Approximately 57% of participants achieved at least 20% weight loss at the highest dose.
SURPASS programme (type 2 diabetes): Consistently showed greater HbA1c reductions and weight loss than semaglutide in head-to-head comparison (SURPASS-2), at comparable doses.
Cardiovascular: SURMOUNT-MMO, examining cardiovascular outcomes in obesity, is ongoing at the time of publication.
Side Effect Profile in Research
Similar pattern to semaglutide but generally reported at lower severity:
- Nausea, diarrhoea, vomiting — common but often milder than equivalent GLP-1 agonist doses
- Constipation
- Injection site reactions
- Better tolerability in direct comparison data is considered a meaningful clinical differentiator
Retatrutide
Mechanism
Retatrutide, developed by Eli Lilly, adds glucagon receptor agonism to the dual GIP/GLP-1 activity of tirzepatide, creating a triple hormone receptor agonist.
This third receptor target is the most mechanistically novel addition. Glucagon receptor activation has traditionally been avoided in metabolic drug development because glucagon raises blood glucose — the opposite of the desired effect in diabetes research. Retatrutide resolves this tension by relying on its GLP-1 component to suppress glucagon's hyperglycaemic effect, allowing the compound to capture glucagon's metabolic benefits without its glycaemic liability.
The researched contributions of glucagon receptor agonism in this context include:
- Enhanced lipolysis: Glucagon directly stimulates fat breakdown in adipose tissue and the liver — contributing to greater fat mass reduction than can be achieved through appetite suppression alone.
- Increased energy expenditure: Glucagon receptor activation increases metabolic rate, thermogenesis, and hepatic fat oxidation — effectively adding a "burn more" mechanism to GLP-1's "eat less" signal.
- Hepatic fat reduction: Glucagon has pronounced effects on hepatic lipid metabolism. Retatrutide studies have observed significant reductions in liver fat content — of particular interest in non-alcoholic fatty liver disease (NAFLD/MASLD) research.
Key Clinical Trial Data
Phase 2 dose-ranging study (published 2023): The published Phase 2 data for retatrutide is among the most striking in the history of obesity pharmacology.
At the highest dose studied (12 mg), participants achieved a mean body weight reduction of 24.2% at 48 weeks — with the trajectory suggesting the plateau had not yet been reached at study end.
Extrapolated to 72 weeks (matching the SURMOUNT-1 timeframe), researchers estimated the trajectory implied potential weight loss in the range of 25-30% — figures that had previously been associated only with bariatric surgery.
Liver fat: Participants with baseline hepatic steatosis showed dramatic reductions in liver fat fraction, with many achieving radiographically normal liver fat levels.
Phase 3: Multiple Phase 3 trials are ongoing at the time of publication. Approval timelines remain speculative.
Side Effect Profile in Research
Broadly consistent with the GLP-1 class:
- Nausea, vomiting, diarrhoea — most frequent, dose-dependent
- Constipation
- Heart rate increases observed — a class effect of glucagon receptor agonism that is monitored carefully in ongoing research
- Higher rates of gastrointestinal side effects at maximum doses compared to tirzepatide, likely attributable to the higher effective GLP-1 activity at escalated doses
Direct Comparison
Weight Loss Outcomes Across Trials
| Compound | Receptors | Trial | Duration | Mean Weight Loss | Placebo |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | STEP 1 | 68 weeks | 14.9% | 2.4% |
| Tirzepatide 15 mg | GLP-1 + GIP | SURMOUNT-1 | 72 weeks | 20.9% | 3.1% |
| Retatrutide 12 mg | GLP-1 + GIP + Glucagon | Phase 2 | 48 weeks | 24.2% | ~3% |
Note: These trials used different populations, inclusion criteria, and durations. Direct cross-trial comparisons have significant limitations and are provided for research context only.
Mechanism Summary
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1 agonism | Yes | Yes | Yes |
| GIP agonism | No | Yes | Yes |
| Glucagon agonism | No | No | Yes |
| Appetite suppression | Strong | Strong | Strong |
| Direct fat cell signalling | No | Yes (GIP) | Yes (GIP + Glucagon) |
| Energy expenditure increase | Moderate | Moderate | Strong (Glucagon) |
| Hepatic fat reduction | Moderate | Moderate | Marked |
| Regulatory approval | Yes (multiple) | Yes (multiple) | Investigational |
| Dosing frequency | Once weekly | Once weekly | Once weekly |
Tolerability
All three compounds share the GLP-1 class side effect profile. Available data suggests:
- Tirzepatide shows better gastrointestinal tolerability than semaglutide at weight-loss doses
- Retatrutide's Phase 2 data showed higher GI side effect rates at maximum doses
- All three compounds use dose escalation schedules to improve tolerability
What the Data Does Not Yet Tell Us
Several important questions remain open in the published literature:
Long-term cardiovascular outcomes for tirzepatide and retatrutide: Semaglutide has robust cardiovascular outcome trial data (SELECT). Tirzepatide's cardiovascular outcome trial is ongoing. Retatrutide's cardiovascular data is limited to Phase 2 safety monitoring. The heart rate increase associated with glucagon receptor agonism in retatrutide trials is being studied carefully in ongoing research.
Weight maintenance after cessation: Data from semaglutide and tirzepatide consistently shows significant weight regain after stopping treatment. Whether retatrutide's greater energy expenditure component changes this pattern is not yet known.
Head-to-head trials: No published trial has directly compared all three compounds in the same population. All cross-compound comparisons are from separate trials with different designs.
Renal and hepatic long-term outcomes: Both retatrutide's hepatic fat findings and the broader renal protective signals observed with GLP-1 agonists are active areas of ongoing study.
Research Context for Each Compound
Semaglutide — the most extensively studied compound in this comparison, with the broadest published evidence base including cardiovascular outcomes data and multiple approved indications. Provides the benchmark against which newer compounds are compared.
Tirzepatide — approved for both type 2 diabetes and obesity. The head-to-head data against semaglutide (SURPASS-2) established superior efficacy at comparable doses. The GIP mechanism has reshaped understanding of incretin biology and may have downstream significance in areas beyond weight loss.
Retatrutide — still investigational at the time of publication. The Phase 2 weight loss data attracted significant scientific attention. Ongoing Phase 3 trials will determine whether the efficacy advantage over approved compounds is maintained in larger, more diverse populations, and what the long-term safety profile looks like.
Frequently Asked Questions
What is the difference between semaglutide and tirzepatide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors. Clinical trial data shows tirzepatide produces greater weight loss at studied doses and may have better gastrointestinal tolerability.
What makes retatrutide different from tirzepatide?
Retatrutide adds glucagon receptor agonism to tirzepatide's dual GLP-1/GIP mechanism. This third receptor contributes enhanced energy expenditure, direct fat oxidation, and pronounced hepatic fat reduction. Phase 2 data showed greater weight loss than either semaglutide or tirzepatide trials, though direct comparisons across trials have significant methodological limitations.
Is retatrutide approved?
Retatrutide remains investigational. Phase 3 trials are ongoing. It is not approved by any regulatory authority at the time of publication.
Can these compounds be compared directly across trials?
With significant caveats. Each compound has been studied in different trial populations, with different inclusion criteria, dose escalation schedules, and study durations. Cross-trial comparisons provide useful research context but cannot substitute for direct head-to-head data.
What is the role of glucagon in retatrutide's mechanism?
Glucagon receptor activation contributes increased energy expenditure and enhanced lipolysis. The hyperglycaemic effect of glucagon is offset by retatrutide's GLP-1 component. This combination produces greater fat loss than appetite suppression alone and notable reductions in liver fat content.
What side effects are shared across all three compounds?
All three compounds are GLP-1 receptor agonists and share the class profile: nausea, vomiting, diarrhoea, and constipation — typically dose-dependent and most pronounced during dose escalation. All three use gradual escalation schedules to improve tolerability.
References
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021 (STEP 1).
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022 (SURMOUNT-1).
Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023 (Phase 2).
Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021 (SURPASS-2).
Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023 (SELECT).
Research Use Only Disclaimer
BioPepTech products are supplied strictly for research use only. They are not intended for human consumption and are not intended to diagnose, treat, cure, or prevent disease.